CRISPR Therapeutics AG (CRSP)
Nasdaq · Common stock · Biological Products, (no Diagnostic Substances)
As of Oct 21, 3:16 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow CRSP in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on CRSP and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
CRSP at a glance
Key statistics
$4.82B
Market capitalization
- Previous close
- $49.88
- Open
- $50.37
- Day range
- $49.60 – $50.50
- Volume
- 734.4K
- Average volume (30 sessions)
- 1.70M
- Shares outstanding
- 96.69M
- Earnings per share
- $(4.67)
- Price / book
- 2.8
- Price / sales
- 360.1
- Beta (1 year, vs SPY)
- 1.90
Where the price sits in its year
52-week range
20% of the range
- Below the 52-week high
- -33.0%
- Above the 52-week low
- +14.0%
Completed sessions through Oct 20, 2026
Technical snapshot
Below its 50-day and 200-day averages
- 20-day average
- $53.10-6.1%
- 50-day average
- $54.80-9.0%
- 200-day average
- $53.08-6.0%
Between the conventional 30 and 70 bands.
-0.4%
1 week
-14.5%
1 month
+5.6%
3 months
-4.9%
Year to date
-27.9%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with CRSP
CRSP on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on CRSP.
See the plans →
Every planScreen names like CRSP
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on CRSP
Put CRSP on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on CRSP
See whether there is an open premium alert on CRSP, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
CRSP headlines
- Global CRISPR-Based Drug Development Platforms Market to Reach USD 0.79 Billion by 2031: Precision Medicine and Gene Therapy Drive Growth
GlobeNewswire Inc. · Jul 3, 2026
- CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows
Investing.com · Feb 20, 2026
SEC Form 4, most recent first
Insider filings
Kulkarni Samarth
+100.0K
Chief Executive Officer, Director · Option exercise
· Oct 16, 2026
Kulkarni Samarth
−100.0K
Chief Executive Officer, Director · Option exercise
· Oct 16, 2026
Kulkarni Samarth
−47.8K
Chief Executive Officer, Director · Open-market sale
$2.38M · Oct 19, 2026
George Simeon
−14.5K
Director · Open-market sale
$720.37K · Oct 14, 2026
George Simeon
−30.0K
Director · Option exercise
· Oct 14, 2026
George Simeon
+30.0K
Director · Option exercise
$420.00K · Oct 14, 2026
Kulkarni Samarth
+8.3K
Chief Executive Officer, Director · Option exercise
· Oct 13, 2026
KASINGER JAMES R.
−2.1K
General Counsel and Secretary · Option exercise
· Oct 13, 2026
About CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Biological Products, (no Diagnostic Substances)
- Headquarters
- Zug
- Employees
- 393
- Listed since
- Oct 19, 2016
- Website
- crisprtx.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.